UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Understanding high-risk smoldering multiple myeloma

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-12

2023

Volltextzugriff (PDF)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

mAbs, 2015-03, Vol.7 (2), p.311-320

2015

Volltextzugriff (PDF)

MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4

Autophagy, 2020-04, Vol.16 (4), p.683-697

2020

Volltextzugriff (PDF)

Smoldering multiple myeloma: biology, clinical manifestations and management

Leukemia & lymphoma, 2022-02, Vol.63 (3), p.518-529

2022

Volltextzugriff (PDF)

MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma

Leukemia & lymphoma, 2024-10, Vol.65 (10), p.1430-1437

2024

Volltextzugriff (PDF)

Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

Expert opinion on therapeutic targets, 2017-01, Vol.21 (1), p.91-101

2017

Volltextzugriff (PDF)

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study

Leukemia & lymphoma, 2021-11, Vol.62 (13), p.3256-3263

2021

Volltextzugriff (PDF)

Extramedullary multiple myeloma

Leukemia & lymphoma, 2013-06, Vol.54 (6), p.1135-1141

2013

Volltextzugriff (PDF)

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study

Leukemia & lymphoma, 2024-06, Vol.65 (6), p.789-799

2024

Volltextzugriff (PDF)

Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States

Leukemia & lymphoma, 2024, Vol.65 (1), p.109-117

2024

Volltextzugriff (PDF)

Function of NLRP3 inflammasome activation in multiple myeloma

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2399367

2024

Volltextzugriff (PDF)

Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review

Annals of medicine (Helsinki), 2024-12, Vol.56 (1), p.2380301

2024

Volltextzugriff (PDF)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients

Cancer biology & therapy, 2024-12, Vol.25 (1), p.2403205

2024

Volltextzugriff (PDF)

Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel

Leukemia & lymphoma, 2023-12, Vol.64 (13), p.2148-2155

2023

Volltextzugriff (PDF)

Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-16

2023

Volltextzugriff (PDF)

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Epigenetics, 2014-11, Vol.9 (11), p.1511-1520

2014

Volltextzugriff (PDF)

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-7

2023

Volltextzugriff (PDF)

CT-defined body composition as a prognostic factor in multiple myeloma

Hematology (Luxembourg), 2023-12, Vol.28 (1), p.2191075-2191075

2023

Volltextzugriff (PDF)

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

Leukemia & lymphoma, 2013-04, Vol.54 (4), p.683-687

2013

Volltextzugriff (PDF)

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

Leukemia & lymphoma, 2014-12, Vol.55 (12), p.2893-2900

2014

Volltextzugriff (PDF)

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

Cell cycle (Georgetown, Tex.), 2018-01, Vol.17 (7), p.858-867

2018

Volltextzugriff (PDF)

The role of cystatin C as a proteasome inhibitor in multiple myeloma

Hematology (Luxembourg), 2020-01, Vol.25 (1), p.457-463

2020

Volltextzugriff (PDF)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2399430

2024

Volltextzugriff (PDF)

Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States

Leukemia & lymphoma, 2021-11, Vol.62 (13), p.3235-3243

2021

Volltextzugriff (PDF)

1 – 25 von 2.388

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.294)
Mit Volltextzugriff
(1.383)

Publikationsform

Artikel
(2.322)
Berichte
(65)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.105)
Life Sciences & Biomedicine
(2.097)
Humans
(1.980)
Multiple Myeloma
(1.425)
Hematology
(1.289)
Oncology
(1.255)
Male
(782)
Multiple Myeloma - Drug Therapy
(765)
Female
(750)
Middle Aged
(717)
Aged
(642)
Multiple Myeloma - Pathology
(501)
Adult
(446)
Multiple Myeloma - Therapy
(436)
Multiple Myeloma - Diagnosis
(357)
Treatment Outcome
(339)
Multiple Myeloma - Complications
(279)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(275)
Prognosis
(274)
Multiple Myeloma - Genetics
(257)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia & Lymphoma
(1.096)
Hematology
(180)
Leukemia & Lymphoma/leukemia And Lymphoma
(125)
Cytotherapy
(61)
Acta Clinica Belgica
(48)
Cancer Biology & Therapy
(48)
Expert Opinion On Biological Therapy
(48)
Expert Opinion On Pharmacotherapy
(48)
Acta Oncologica
(47)
Oncoimmunology
(47)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Understanding high-risk smoldering multiple myeloma

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4

Smoldering multiple myeloma: biology, clinical manifestations and management

MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma

Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study

Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study

Extramedullary multiple myeloma

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study

Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States

Function of NLRP3 inflammasome activation in multiple myeloma

Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients

Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel

Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

CT-defined body composition as a prognostic factor in multiple myeloma

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

The role of cystatin C as a proteasome inhibitor in multiple myeloma

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States

Aktive Filter

Suchergebnisse filtern